よむ、つかう、まなぶ。
参考資料3 有効性評価に基づく大腸がん検診ガイドライン2024年度版 (73 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_71872.html |
| 出典情報 | がん検診のあり方に関する検討会（第46回 3／23）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
113. NHS England and NHS improvement. Shared Decision-Making: Summary
Guide. [Ayailable from: https:/がwww.england.nhs.uk/wp・
content/uploads/2019/01/shared-decision-making-summary-guide-y1.pdfl
114. US Preyentive Services Task Force: Davidson KW Mangione CM, Barry MJ,
Nicholson WK. Cabana MD, Caughey AB, Davis EM, Donahue KE, Doubeni CA,
Kubik M, Li L, Ogedegbe G, Pbert L, Silveystein M, Stevermer J, Tseng CW,
Wong JB. Collaboration and Shared Decision-Making Between Patients and
Ciinicians in Preyentive Health Care Decisions and US Preventive Services 1ask
Force Recommendations. JAMA. 2022:327(12):1171-6. doi:
10.1001/jama.2022.3267. PMID 835315879
115. Stacey D, L6gare F Lewis 氏, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner
ML Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for
peop】e facing health treatment or screening decsons. Cochrane Database Syst
Rev 2017:4(4:CD001481. doi: 10.1002714651858.CD001431.pub5. FM1D:
28402085
116. Pepe MS, Etzioni R, Feng Z, Potter JD、 Thompson ML, Thornquist M, Winget M,
Yasui Y. Phases of Biomarker Development for Early Detection of Cancer. り Natl
Cancer Inst. 2001:93(14):1054-61. doi: 10.1093jnc93.14.1054. PMID: 11459866
117. Lord SJ, Irwig L, Simes RJ. When 1s Mieasuring Sensitivity and Specificity
Suffeient To Byvaluate a Diagnostic Test, and When Do We Need Randomized
Trials? Ann 1ntern Med. 2006:144(11):850-5. doi: 10.7326/0003-4819-144-11-
200606060-00011. PMID 16754927
118. van Rossum LG, yan Rijn AE Laheij RJ, van Oijen MO, Fockens P van Kmeken
HH, Verbeek ATL, Jansen JB, Dekker EE. Random Comparison of Guaiac and
TImmunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening
Population. Gastroenterology. 2008:135(1):82-90. doi:
10.1053放.gastro.2008.03.040. PMID: 18482589
119. Irwig L, Houssami N, Armstrong B, Glasziou P Evaluating new screening tests
for breast cancer. BMJ. 2006:3327548):678-9. doi: 10.1136/bmj.382.7543.678.
PMID: 16565097
73
Guide. [Ayailable from: https:/がwww.england.nhs.uk/wp・
content/uploads/2019/01/shared-decision-making-summary-guide-y1.pdfl
114. US Preyentive Services Task Force: Davidson KW Mangione CM, Barry MJ,
Nicholson WK. Cabana MD, Caughey AB, Davis EM, Donahue KE, Doubeni CA,
Kubik M, Li L, Ogedegbe G, Pbert L, Silveystein M, Stevermer J, Tseng CW,
Wong JB. Collaboration and Shared Decision-Making Between Patients and
Ciinicians in Preyentive Health Care Decisions and US Preventive Services 1ask
Force Recommendations. JAMA. 2022:327(12):1171-6. doi:
10.1001/jama.2022.3267. PMID 835315879
115. Stacey D, L6gare F Lewis 氏, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner
ML Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for
peop】e facing health treatment or screening decsons. Cochrane Database Syst
Rev 2017:4(4:CD001481. doi: 10.1002714651858.CD001431.pub5. FM1D:
28402085
116. Pepe MS, Etzioni R, Feng Z, Potter JD、 Thompson ML, Thornquist M, Winget M,
Yasui Y. Phases of Biomarker Development for Early Detection of Cancer. り Natl
Cancer Inst. 2001:93(14):1054-61. doi: 10.1093jnc93.14.1054. PMID: 11459866
117. Lord SJ, Irwig L, Simes RJ. When 1s Mieasuring Sensitivity and Specificity
Suffeient To Byvaluate a Diagnostic Test, and When Do We Need Randomized
Trials? Ann 1ntern Med. 2006:144(11):850-5. doi: 10.7326/0003-4819-144-11-
200606060-00011. PMID 16754927
118. van Rossum LG, yan Rijn AE Laheij RJ, van Oijen MO, Fockens P van Kmeken
HH, Verbeek ATL, Jansen JB, Dekker EE. Random Comparison of Guaiac and
TImmunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening
Population. Gastroenterology. 2008:135(1):82-90. doi:
10.1053放.gastro.2008.03.040. PMID: 18482589
119. Irwig L, Houssami N, Armstrong B, Glasziou P Evaluating new screening tests
for breast cancer. BMJ. 2006:3327548):678-9. doi: 10.1136/bmj.382.7543.678.
PMID: 16565097
73